Lasmiditan Discontinuation, DAAN Designation, Alteplase for Eye Stroke
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the discontinuation of lasmiditan, the new DAAN designation, and the use of alteplase after eye stroke.
No reviews yet